USDA withdraws a plan to limit salmonella levels in raw poultry
The Agriculture Department will not require poultry companies to limit salmonella bacteria in their products, halting a Biden Administration effort to prevent food poisoning from contaminated meat.
The department on Thursday said it was withdrawing a rule proposed in August after three years of development. Officials with the USDA's Food Safety and Inspection Service cited feedback from more than 7,000 public comments and said they would 'evaluate whether it should update' current salmonella regulations.
The rule would have required poultry companies to keep levels of salmonella bacteria under a certain threshold and test for the presence of six strains most associated with illness, including three found in turkey and three in chicken. If the levels exceeded the standard or any of those strains were found, the poultry couldn't be sold and would be subject to recall, the proposal had said.
The plan aimed to reduce an estimated 125,000 salmonella infections from chicken and 43,000 from turkey each year, according to USDA. Overall, salmonella causes 1.35 million infections a year, most through food, and about 420 deaths, according to the U.S. Centers for Disease Control and Prevention.
The withdrawal drew praise from the National Chicken Council, an industry trade group, which said the proposed rule was legally unsound, misinterpreted science, would have increased costs and create more food waste, all 'with no meaningful impact on public health.'
'We remain committed to further reducing salmonella and fully support food safety regulations and policies that are based on sound science,' said Ashley Peterson, the group's senior vice president of science and regulatory affairs.
But the move drew swift criticism from food safety advocates, including Sandra Eskin, a former USDA official who helped draft the plan.
The withdrawal 'sends the clear message that the Make America Healthy Again initiative does not care about the thousands of people who get sick from preventable foodborne salmonella infections linked to poultry,' Eskin said in a statement.
The proposed rule had been regarded as a food safety victory similar to a 1994 decision to ban certain strains of dangerous E. coli bacteria from ground beef after deadly outbreaks, said Sarah Sorscher, of the Center for Science in the Public Interest.
During Elections
Get campaign news, insight, analysis and commentary delivered to your inbox during Canada's 2025 election.
'Make no mistake: Shipping more salmonella to restaurants and grocery stores is certain to make Americans sicker,' Sorscher said.
Earlier this month, the USDA said it would delay by six months the enforcement of a final rule regulating salmonella levels in certain breaded and stuffed raw chicken products. Enforcement, which was set for May 1, now begins Nov. 3.
That covers foods such as frozen chicken cordon bleu and chicken Kiev dishes that appear to be fully cooked but are only heat-treated to set the batter or coating. Such products have been linked to at least 14 salmonella outbreaks and at least 200 illnesses since 1998, according to the CDC.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Japan Forward
an hour ago
- Japan Forward
AI Tool 'KIBIT': A Game Changer in New Drug Development
このページを 日本語 で読む The COVID-19 pandemic reminded the world of the importance of drug discovery. However, modern drug discoveries require massive financial investment. Meanwhile, the use of artificial intelligence for AI drug discovery is gaining attention as a way to control soaring pharmaceutical prices. And a Japanese-made AI tool named 'KIBIT' is about to open up a new stage in this field. President Donald Trump issued executive orders in April and May mandating the reduction of domestic drug prices in the United States. Accompanying White House fact sheets refer to the high cost Americans pay for prescriptions, which is 2.78 times higher than the OECD average. Prescription costs are also 3.47 times higher than in Japan. Trump sees these high costs to consumers as a serious issue. In Japan, a national drug pricing system sets medication prices, enabling access to affordable treatments due to governmental oversight. In contrast, US pharmaceutical companies can set prices freely. This often results in higher charges than in other countries. Following his May 12 executive order, Trump stated that his orders would cut prices by 59% to as much as 90% to align with the levels of other countries. This could potentially result in significant revenue losses for the pharmaceutical industry. In the case of Japan, major pharmaceutical companies such as Takeda Pharmaceutical Company Limited and Astellas Pharma Inc earn over 30% of their revenue from the US. According to his comments, the President could impose additional tariffs on foreign-manufactured drugs if prices are not reduced. In the search for new drugs and treatments (Screenshot, ©FRONTEO Inc) One major reason for rising drug prices is the increasing cost of research and development. The average R&D spending by Japanese pharmaceutical companies rose from ¥30.2 billion JPY ($298.7 million USD) in 1993 to 163.3 billion ($1.13 billion) in 2019 — a 5.4-fold increase over 26 years. US companies saw an even sharper rise, from $841 million (¥121.1 billion) to $7.449 billion (¥1.0725 trillion). That marked an 8.8-fold increase. Moreover, investing in R&D doesn't guarantee success. The probability of developing a successful drug in Japan dropped from 1 in 13,000 two decades ago to 1 in 23,000 recently. Despite the increasing costs, results are scarce. Consequently, the R&D-to-revenue ratio rose from about 10% in 1993 to around 18% in 2019 in both countries. Introducing KIBIT. (Screenshot ©FRONTEO Inc) AI is being eyed as a solution to reduce R&D costs by dramatically cutting time and expenses. Drug development involves four stages: Basic research & target identification Compound optimization Preclinical trials and Clinical trials. Many AI vendors are involved in drug discovery. In particular, they focus on reducing costs in the third (preclinical) and fourth (clinical) stages. However, most companies have yet to tackle the critical first stage — target identification. Introducing KIBIT. (Screenshot, ©FRONTEO Inc) The first enterprise to address this initial stage is the Japanese company FRONTEO. Utilizing its proprietary natural language processing AI engine KIBIT, the company analyzes vast medical and pharmaceutical literature to generate innovative drug ideas that researchers may not have considered. Human thinking is inherently biased. The more experienced a researcher is, the more difficult it becomes to identify novel molecular targets. Stated another way, the bias of experience often blocks new ideas. KIBIT, however, is free from such biases. It identifies new molecular targets that might be effective against specific diseases. To do so, it analyzes vast amounts of academic literature. It can even derive specific hypotheses. Furthermore, KIBIT can identify and suggest highly disease-relevant target molecules that are not explicitly mentioned in the literature. This significantly enhances drug discovery potential. How KIBIT works. (Screenshot, ©FRONTEO Inc) Only a few countries have the capacity to develop new drugs. In 2024, among newly approved pharmaceuticals in Japan, the US, and Europe, the US led with 143 products. Japan followed with just 12, roughly equal to the United Kingdom's 10. According to the statistics "Nationalities of companies creating the top 100 drugs in the world by sales (2022),": United States – 52 United Kingdom – 10 Switzerland – 9 Germany – 8 Denmark – 8 Japan – 7 Most countries, other than the US, struggle to produce blockbuster drugs. In this context, hopes are high for FRONTEO's KIBIT. If it can consistently generate innovative new drugs efficiently, it may help deliver affordable medicines to those in need, without Mr Trump's intervention. FRONTEO's AI drug discovery service, utilizing KIBIT, is already being adopted by several major pharmaceutical companies. Those leveraging KIBIT to create new drugs could become game changers in the industry. This article is contributed by FRONTEO Inc, a supporting member of JAPAN Forward. (Read the report in Japanese.) Author: FRONTEO Inc. このページを 日本語 で読む
Winnipeg Free Press
14 hours ago
- Winnipeg Free Press
Takeaways from AP's report on financial interests of RFK Jr. adviser who runs wellness platform
ASSOCIATED PRESS (AP) — Calley Means has built a following by railing against the U.S. health system, often hammering on alleged financial conflicts within the medical establishment. Means, a top aide to Health Secretary Robert F. Kennedy Jr., was hired as a White House adviser in March. He has used that position to accuse physician groups, federal agencies and government scientists of financial interests that bias their work. Means, however, has his own stake in the sprawling health system. He's the co-founder of an online platform that offers dietary supplements, herbal remedies, exercise equipment, light therapy lamps and other wellness products. The Associated Press found that Means' heated rhetoric against the medical mainstream dovetails with the interests of his company TrueMed, which features vendors who are prominent supporters of Kennedy's 'Make America Healthy Again' movement. Because of his status as a temporary government employee, Means is exempt from publicly disclosing his financial details. The AP reviewed more than two dozen interviews, speeches, articles and podcast appearances by Means both before and after he joined the government. Here are some takeaways from the AP's reporting: Attacking prescription drugs, promoting wellness alternatives Means' company, Truemed, helps users take tax-free money out of their health savings accounts, or HSAs, to spend on things that wouldn't normally qualify as medical expenses, such as meal delivery services and homeopathic products — remedies based on a centuries-old, debunked theory of medicine. As a top messenger for the administration, Means has been promoting a new government report that calls for scaling back prescription drugs for depression, weight loss and other conditions. By criticizing the use of drugs and other rigorously tested products, health experts say Means is furthering the interests of his company, which offers alternatives to traditional medicine. 'It reeks of hypocrisy,' said Dr. Reshma Ramachandran, a health researcher at Yale University. 'In effect, he is representing another industry that is touting nonregulated products and using his platform within the government to financially benefit himself.' In a written statement, Means said his government work has not dealt with matters affecting Truemed and has focused on issues like reforming nutrition programs and pressuring companies to phase out food dyes. 'Pursuing these large-scale MAHA goals to make America healthy has been the sole focus in my government work,' Means said. Undisclosed interests The full extent of Means' potential financial conflicts are unclear because of his status as a special government employee. Unlike presidential appointees and other senior officials, special government employees do not have to leave companies or sell investments that could be impacted by their work. Also, their financial disclosure forms are shielded from public release. 'It's a big problem,' says Richard Painter, former White House ethics lawyer under George W. Bush. 'I think it's a loophole.' Plugging products and business associates While promoting the administration's accomplishments, Means has not shied away from plugging his own brand or those of his business partners. When asked to offer health advice to listeners of a sports podcast, Outkick The Show, in April, Means suggested they read his book 'Good Energy,' which he co-authored with his sister, Dr. Casey Means. He also recommended blood tests sold by Function Health, which provides subscription-based testing for $500 annually. The company was cofounded by Dr. Mark Hyman, a friend of Kennedy and an investor in Truemed, which also offers Hyman's supplements through its platform. Like dietary supplements, the tests marketed by Function Health are not clinically approved by the Food and Drug Administration. 'It ends up favoring these products and services that rest on flimsy grounds, at the expense of products that have actually survived a rigorous FDA approval process,' said Dr. Peter Lurie, a former FDA official who is now president of the Center for Science in the Public Interest. Steering medical dollars into health savings accounts Means says he has not worked on issues impacting HSAs since joining the federal government. Federal ethics laws forbid government employees from taking part in decisions that could impact their financial situation. But before joining government, Means said the mission of his company 'is to steer medical dollars into flexible spending.' 'I want to get that $4.5 trillion of Medicare, Medicaid, everything into a flexible account,' he told fitness celebrity Jillian Michaels, on her podcast last year. Truemed collects fees when users and partnering companies use its platform. Means also founded a lobbying group, made up of MAHA entrepreneurs and TrueMed vendors, that listed expanding HSAs as a goal on its website. Means said in a statement that the group focused only on broad topics like 'health care incentives and patient choice — but did not lobby for specific bills.' Benefits of HSAs questioned Expanding HSAs has been part of the Republican health platform for more than 20 years. The tax-free accounts were created in 2003 to encourage Americans in high-deductible plans to be judicious with their health dollars. But HSAs have not brought down spending, economists say. They are disproportionately used by the wealthiest Americans, who have more income to fund them and bigger incentives to lower their tax rate. Americans who earn more than $1 million annually are the group most likely to make regular HSA contributions, according to an analysis by the nonprofit Center on Budget and Policy Priorities. Most Americans with HSAs have balances less than $500. HSA expansions in Trump's 'One Big Beautiful Bill' are projected to cost the federal government $180 billion over the next 10 years. 'These are really just tax breaks in the guise of health policy that overwhelmingly benefit people with high incomes,' said Gideon Lukens, a former White House budget official during the Obama and Trump administrations. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Toronto Star
18 hours ago
- Toronto Star
Top RFK Jr. aide attacks US health system while running company that promotes wellness alternatives
WASHINGTON (AP) — Calley Means has built a following within the 'Make America Healthy Again' movement by railing against the failings of the U.S. health system, often pinning the blame on one issue: corruption.
